We are the leading funder of brain tumour research in the UK, committing over £41.2 million to date on pioneering projects that will help adults and children with brain tumours.
We fund research through a competitive, fair and transparent process of best practice called peer review to ensure we only select the very best research that will have a real impact on those affected by brain tumours.
As part of our research strategy, A Cure Can't Wait, we have established various funding opportunities to achieve our goals of doubling survival and halving the harm caused by a brain tumour. Please see below to find out more about the different types of grants we fund:
Our Expanding Theories award provides funding to researchers looking at innovative approaches that could change our understanding, the diagnoses, and/or management of brain tumours.
This project is researching the role of transcription factors in tumour survival and growth.
Research testing new technology to understand tumour resistance to treatments.
Research testing non-invasive techniques to diagnose and monitor low-grade tumours.
Research that aims to identify new drug combination to improve survival for patients with high-grade gliomas.
These projects are testing ideas that haven't been tried in brain tumours previously, to make new discoveries for the field.
This research involves innovative approaches that could change our understanding, diagnosis and management of brain tumours.
Our Quest for Cures grant programme provides funding for collaborative teams from around the world with transformational research ideas.
Understand the changes that drive medulloblastoma resistance to treatment.
Research programme bringing together experts to developing targeted treatments for ACPs.
This research acknowledges the importance of international and interdisciplinary team approaches to accelerate research.
These programmes bring together global teams from different disciplines to target the research from different approaches.
This award funds future scientific leaders of research into the causes and treatment of brain tumours.
Investigating the cells which give rise to Group 3 and 4 medulloblastoma.
Our Quality of Life grant programme is key to our 'halve the harm' part of our strategy. It provides funding to researchers looking to increase our understanding and minimise the impact of brain tumours on people's daily lives.
Learn more about our groundbreaking £5 million investment for research into Paediatric Low Grade Brain Tumours.
PNET5 aims to prove that children diagnosed with a lower risk medulloblastoma would benefit from less aggressive treatment
We're partnering with the Structural Genomics Consoritum, funding two researchers who will be searching for new drugs.